为解决这一问题，团队借鉴了制造弹性强橡胶的分子设计，采用"可折叠瓶刷"结构，使材料既坚固又极 具弹性。聚合物分子具有许多柔韧的侧链从中央骨架辐射，这些侧链可像手风琴一样折叠，储存可展开 的额外长度，从而实现高拉伸性。他们将折叠瓶刷聚合物概念应用于PEG，通过将前体混合物暴露在紫 外线下几秒钟，启动聚合形成瓶刷结构网络，成功制造出可3D打印、高度可拉伸的PEG基水凝胶和无 溶剂弹性体。 团队成员表示，通过改变紫外线灯的形状，可以创造出许多复杂的结构，这为未来制造人造器官或药物 递送系统提供了新可能。此外，实验表明，这种可拉伸的3D打印PEG材料对生物友好，细胞培养测试 证实其与生物组织兼容，适用于体内材料如器官支架。 美国弗吉尼亚大学研究团队首创了一种新型3D打印材料。该材料与人体免疫系统兼容，有望推动人造 器官移植和药物递送等诸多医疗技术实现快速、安全发展。这一突破性成果发表于最新一期《先进材 料》期刊。 展望未来，该材料可能与其他材料结合，制造具有不同化学成分的3D打印产品，可拓展多种应用。例 如，与现有固态聚合物电解质相比，新材料在室温下展现出更高的电导率和拉伸性，凸显了其作为先进 电池技术中高性能固态电 ...

Core Viewpoint - The leading domestic hyaluronic acid company, Huaxi Biological, has publicly criticized 10 research reports from 9 securities firms for containing misleading statements, highlighting the competitive dynamics between hyaluronic acid and recombinant collagen products [1][2][3] Group 1: Criticism of Research Reports - Huaxi Biological published a nearly 5000-word article accusing the reports of creating inflated expectations around recombinant collagen products at the expense of the hyaluronic acid industry [2][3] - The criticized reports include those from major firms such as Huatai Securities, Ping An Securities, and Western Securities, with specific claims of bias and contradictions in their analyses [3][5][12] - Some reports have been reportedly deleted, particularly the one from Western Securities, raising questions about the integrity of the research [5][22] Group 2: Market Dynamics and Product Comparison - The reports discussed the advantages and disadvantages of hyaluronic acid and recombinant collagen, with some showing a preference for collagen, which has led to concerns about the objectivity of the analyses [7][16] - Huaxi Biological's core product is hyaluronic acid, while the competitor, Juzhi Biological, focuses on recombinant collagen, both of which are used in medical and cosmetic applications [3][19] - The market for recombinant collagen is expected to grow rapidly, potentially surpassing that of hyaluronic acid, due to its higher technical barriers and product characteristics [20][19] Group 3: Analyst Reactions and Industry Implications - The incident has sparked discussions among analysts, with some suggesting that securities firms may feel pressured to remain silent due to their weaker position against prominent companies like Huaxi Biological [23][22] - Analysts have noted that while both products have their merits, the technical complexity of recombinant collagen is higher than that of hyaluronic acid, reflecting broader trends in consumer preferences [23][20] - Despite the criticism, several securities firms continue to issue positive ratings for Huaxi Biological, indicating a complex relationship between market perception and research integrity [22][19]